Tel-Array's Board of Directors consists of four members representing management and shareholders. Members have diverse backgrounds and each bring unique value to Tel-Array's Board.
William Campbell, Co-Founder
Dr. Campbell is a co-founder of Tel-Array Diagnostics Inc. He has more than 50 years of research experience in the areas of protein and peptide chemistry. He was an associate professor at Nagoya City University and Choju Medical Institute in Japan, during which he discovered a novel carboxypeptidase, CPR, an important enzyme with dual functions as a regulator of fibrinolysis and inflammation. Also in Japan, he co-developed a genetic algorithm that designs peptides that bind to specific targets in proteins, one of which inhibits HIV reverse transcriptase and prevents viral replication. In 2000, he returned to Canada and joined the Brain Research Centre of the University of British Columbia as a visiting scientist. He developed a peptide array-based technology that allowed identification of SARS epitopes for the development of a SARS vaccine. In recent years, he was involved in several biotechnology start-up companies. He found and served as the Chief Executive Officer of PepMetric Technologies, which provided peptides and peptide arrays to the scientific community. Dr. Campbell received his B.Sc. from Concordia University and his Ph.D. from the University of Montreal. His work has been published in some of the most prestigious scientific journals including Nature Medicine, Immunological Reviews, Journal of Biological Chemistry, and Chemistry & Biology.
Cherie Cheng, Shareholder
Ms. Cheng received her Bachelor of Commerce degree in Accounting from the University of British Columbia in 2004, followed by her Canadian CGA designation in 2008. She has supervised financial teams, implemented fiscal policies and overseen business management systems and control procedures in China and other Asia-Pacific regions. Ms. Cheng's recent roles in Canada include Chief Accountant of Monument Mining Inc. and President of Chercan Enterprises. In China, Ms. Cheng is an investment consultant of Speedycloud.cn; Financial Manager of Guangzhou Jiuzhi Pharmaceuticals; and Financial Manager of HW Group Holdings (Australia). She has extensive experience as a founder and director of businesses in pharmaceutical, high technology and real estate industries.
Qiuming Gong, Shareholder
Mr. Gong graduated from Nanjing University of Chemical Technology with a Bachelor of Chemical Engineering degree in 1986. He is a senior engineer with extensive experience in research and development in the fields of water treatment, biochemical engineering, oilfield chemicals and environmental protection. Mr. Gong's major scientific and technological achievements include publishing more than 10 scientific papers and filing 6 invention patents in China. He is a member of the Chinese government's expert panel in science and technology evaluation and government procurement evaluation. From 1986 to 1996, Mr. Gong worked at CNOOC Tianjin Chemical Research & Design Institute as Project Manager, Team Leader and Senior Engineer. Since 1996, he has been the founder of several companies in China including Tianjin Kudos Group, Beststar Industrial Ltd. and Cansda Technology Ltd. (Tianjin). Mr. Gong is also the Chairman of Cansda Oiltech International Inc. of China.
Hong Zhang, Co-Founder, CEO & CSO
Dr. Zhang is a co-founder of Tel-Array. He has over 20 years of research and product development experience in the fields of signal transduction, proteomics and cancer biomarkers from academia and industry. He was the Director of Research and Development at Kinexus Bioinformatics Corporation for 12 years. During his tenure at Kinexus, he oversaw the company’s research programs and pioneered the development of a suite of proteomics microarray-based screening platforms that have been widely adopted by the world leading pharmaceutical companies in their drug discovery and development efforts. Dr. Zhang received his Ph.D. degree in Cell and Molecular Biology from the University of British Columbia in 2000 and completed 3 years of post-doctoral training at the University of British Columbia Brain Research Center. He also holds a M.Sc. in Biochemistry and a B.Sc. in Biology. Before moving to Canada, he served as an assistant professor in the Fujian Normal University. He has authored over 25 original research publications in prestigious peer-reviewed journals and several reviews and book chapters on the subjects of proteomics and signal transduction